Unicycive Historical Income Statement
| UNCY Stock | USD 0.68 0 0.29% |
Historical analysis of Unicycive Therapeutics income statement accounts such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K, Depreciation And Amortization of 386.4 K or Selling General Administrative of 4.4 M can show how well Unicycive Therapeutics performed in making a profits. Evaluating Unicycive Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Unicycive Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Unicycive Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Unicycive Therapeutics is a good buy for the upcoming year.
Unicycive |
About Unicycive Income Statement Analysis
Unicycive Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Unicycive Therapeutics shareholders. The income statement also shows Unicycive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Unicycive Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Unicycive Therapeutics. It is also known as Unicycive Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Unicycive Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Unicycive Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Unicycive Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 386.4 K in 2024, whereas Interest Expense is likely to drop slightly above 77.9 K in 2024.
Unicycive Therapeutics income statement Correlations
Click cells to compare fundamentals
Unicycive Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Unicycive Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 139K | 244K | 628K | 6K | 82K | 77.9K | |
| Ebit | (2.0M) | (2.0M) | (9.0M) | (18.1M) | (30.5M) | (28.9M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.